Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR1F | P30939 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1940263 | 0.84 | CNR2 (0.42) | DRD2HTR1A | |
| SCHEMBL1940311 | 0.81 | ACHE (0.49) | ACHEGRM4CYP1A2DRD2SLC6A4 | |
| SCHEMBL1940065 | 0.81 | ACHE (0.49) | ACHEGRM4CYP1A2DRD2SLC6A4 | |
| SCHEMBL12026856 | 0.76 | HIF1A (0.49) | ACHEGRM4DRD2HTR1AHIF1A | |
| SCHEMBL23175432 | 0.70 | DRD2 (0.42) | ACHEDRD2SLC6A4HTR1ASCD | |
| SCHEMBL1941113 | 0.69 | STS (0.59) | — | |
| SCHEMBL1941068 | 0.69 | STS (0.59) | — | |
| SCHEMBL11224845 | 0.69 | ESR1 (0.46) | HTR1AHTR1FSCD | |
| SCHEMBL15680242 | 0.69 | ESR1 (0.39) | — | |
| SCHEMBL5189820 | 0.68 | ACHE (0.39) | ACHEGRM4CYP1A2DRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173679-B2 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERMAMEX (MC) | 2012-05-08 | — | — | US | disclosed |
| US-20110237624-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | LABORATOIRE THERAMEX (MC) | 2011-09-29 | — | — | US | disclosed |
| US-7977364-B2 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERMAMEX (MC) | 2011-07-12 | — | — | US | disclosed |
| EP-1812404-B1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | THERAMEX (MC) | 2011-06-15 | — | — | EP | disclosed |
| US-20090023779-A1 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERAMEX (FR) | 2009-01-22 | — | — | US | disclosed |
| EP-1812404-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | LABORATOIRE THERAMEX (MC) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006040351-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | LABORATOIRE THERAMEX (MC) | 2006-04-20 | — | — | WO | disclosed |
| EP-1647549-A1 | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents | LABORATOIRE THERAMEX (MC) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023779-A1 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | ESR1, ESR2, GPER1 | ACHE 1147/4885GRM4 1151/4885CYP1A2 29/4885 |
| US-20110237624-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | ESR1, ESR2, GPER1 | ACHE 1147/4885GRM4 1151/4885CYP1A2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.